Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLC

15 Jul 2023

Abstract excerpt

Although concurrent chemoradiation (CRT) and durvalumab consolidation has become a standard treatment for stage III non-small cell lung cancer (NSCLC), clinicopathologic and genomic factors associated with its efficacy remain poorly characterized. Here, in a multi-institutional retrospective cohort study of 328 patients treated with CRT and durvalumab, we identify that very high PD-L1 tumor proportion score (TPS)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Colorectal Cancer Treatments and Studies
Share to Gastric Cancer Management and Outcomes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37454214
DOI: 10.1038/s41467-023-39874-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of TMB/PD-L1 expression and pneumonitis on chemoradiation and durvalumab response in stage III NSCLCPMID 37454214Read ↗

Impact of TMB, PD-L1 expression, and pneumonitis on outcomes to chemoradiation and durvalumab in unresectable stage III non-small cell lung cancersSemantic proximity Read ↗

Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.Semantic proximity Read ↗

Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).Semantic proximity Read ↗

Brief report: impact of consolidation durvalumab on unresectable non-small cell lung cancer with driver mutations.Semantic proximity Read ↗

Maintenance therapy for metastatic non-squamous non-small cell lung cancer: lymphopenia as a biomarker for pemetrexed cessationSemantic proximity Read ↗

Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.Semantic proximity Read ↗

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.Semantic proximity Read ↗

Real-world outcomes of chemoradiotherapy for unresectable Stage III non-small cell lung cancer: The SOLUTION study.Semantic proximity Read ↗

Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study.Semantic proximity Read ↗

PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC.Semantic proximity Read ↗

Towards a Survival Risk Prediction Model for Metastatic NSCLC Patients on Durvalumab Using Whole-Lung CT RadiomicsSemantic proximity Read ↗

Durable response to durvalumab-based immunochemotherapy in small-cell lung carcinoma transformation from EGFR-mutant non-small cell lung cancer: A case report.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.